Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Labcorp Holdings LH in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 3 | 2 | 1 | 0 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 1 | 1 | 0 | 0 | 0 |
2M Ago | 2 | 1 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $273.0, with a high estimate of $286.00 and a low estimate of $265.00. This current average has increased by 3.1% from the previous average price target of $264.80.
Exploring Analyst Ratings: An In-Depth Overview
A clear picture of Labcorp Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Jack Meehan | Barclays | Raises | Equal-Weight | $271.00 | $249.00 |
Kevin Caliendo | UBS | Lowers | Buy | $286.00 | $293.00 |
Elizabeth Anderson | Evercore ISI Group | Raises | Outperform | $265.00 | $260.00 |
Ricky Goldwasser | Morgan Stanley | Raises | Overweight | $270.00 | $260.00 |
Derik De Bruin | B of A Securities | Raises | Buy | $271.00 | $262.00 |
Brian Tanquilut | Jefferies | Announces | Buy | $275.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Labcorp Holdings. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Labcorp Holdings compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Labcorp Holdings's stock. This examination reveals shifts in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Labcorp Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Labcorp Holdings analyst ratings.
Get to Know Labcorp Holdings Better
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Labcorp Holdings: Financial Performance Dissected
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Labcorp Holdings showcased positive performance, achieving a revenue growth rate of 7.37% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Labcorp Holdings's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.16%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Labcorp Holdings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.09%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.96%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Labcorp Holdings's debt-to-equity ratio is below the industry average at 0.94, reflecting a lower dependency on debt financing and a more conservative financial approach.
What Are Analyst Ratings?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.